Tadalafil, the erectile dysfunction drug sold as Cialis, is being marketed through direct-to-consumer telehealth clinics as a general-purpose longevity treatment, promising benefits for the heart, the brain, and athletic performance. One such company, AgelessRx, sells a low-dose monthly prescription for about $70, and its medical director has said the data are strong enough to offer it to both men and women over 40.
None of those uses is approved. The drug is cleared in the United States for erectile dysfunction, for a rare form of high blood pressure affecting the lungs, and for symptoms of an enlarged prostate. It is not approved to prevent heart attack or stroke, and it is certainly not approved to extend life.
The uncomfortable part, and the reason this is not a simple debunking, is that the observational evidence pointing toward a cardiovascular benefit is real and unusually consistent. What does not exist is a trial that would establish whether the drug is causing the benefit or merely marking out a healthier group of patients.
The Studies Behind the Enthusiasm, and Their Shared Weakness
The mechanism is well understood. Tadalafil belongs to a class of drugs known as PDE5 inhibitors, which prevent the breakdown of a signaling molecule, thereby relaxing smooth muscle and widening blood vessels throughout the body. That effect is not confined to one region. Sildenafil, the first drug in the class, was originally developed to treat chest pain due to poor blood flow to the heart before its other effects redirected its use.
The headline findings are based on analyses of medical records. An analysis of more than 8,000 men prescribed tadalafil, published in Clinical Cardiology, found a 55 percent lower rate of death from cardiovascular causes and a 44 percent lower rate of death from any cause during the study period. A separate analysis drawing on more than half a million patients, led by Dietrich Jehle of the University of Texas Medical Branch, reported a 32 percent lower risk of dementia among those taking the drug.
Every one of those studies is retrospective and observational. They can show association and nothing more. Men who seek treatment for erectile dysfunction differ from men who do not in ways records cannot fully capture, including engagement with the health system and willingness to take a daily medication. Robert Kloner, chief science officer at the Huntington Medical Research Institute and a professor at the University of Southern California, whose lab conducted the tadalafil analysis, calls the pattern "a very interesting signal" while emphasizing that prospective trials are needed, according to reporting by NPR. Supporting evidence for vessel effects comes mostly from small human trials and laboratory work.
There is a structural reason the trials have not happened. Generic versions are already on the market, so no manufacturer has a commercial incentive to fund the expensive studies that would settle the question. Kloner also notes that the drugs are far less studied in women, who are nonetheless being offered them by longevity clinics.
The pattern is not unique to this drug. MedicalDaily recently reported on a sevenfold rise in pediatric prescribing of another repurposed medication after prominent figures promoted it, in that case, while the supporting evidence was weakening rather than strengthening. Public enthusiasm for an off-label use routinely outruns the research meant to test it, and the gap is widest where a cheap generic removes any commercial reason to close it.
A Specialist Panel Drew a Narrower Line Than the Marketing Does
There are signs of movement inside conventional medicine, and the shape of that movement is instructive. The Princeton Consensus Panel, a group focused on men's sexual function and cardiovascular health, reached consensus language at its most recent meeting that low-dose tadalafil is appropriate for a subset of men at elevated cardiovascular risk from arterial plaque buildup. Those formal recommendations have not yet been published.
Martin Miner, who directs the Men's Health Center at Brown University and co-chaired the meeting, said some participants were hesitant to endorse broader use without randomized trials but ultimately did so based on observational evidence. He also drew a clear line, saying it is not for all men.
That is a considerably narrower claim than a subscription sold to anyone over 40. Steve Nissen, chief academic officer of the Cleveland Clinic Heart, Vascular and Thoracic Institute, put the objection plainly, telling NPR that an absence of evidence of harm does not mean there is no harm, and that the use is hard to justify without randomized trial data. Kloner, who is broadly sympathetic to the research, adds that cardiologists are not routinely recommending it.
Interactions and Costs Worth Raising Before Anything Else
The most important safety point is specific, not general. PDE5 inhibitors must not be combined with nitrate medications used for chest pain, because the combination can cause a dangerous drop in blood pressure. They also interact with alpha blockers commonly prescribed for prostate symptoms and blood pressure, and with certain other drugs. Anyone considering this needs a clinician who knows their full medication list, which is precisely the review a quick online questionnaire is least suited to perform.
Reported side effects include headache, flushing, indigestion, back pain, and nasal congestion. Sudden vision or hearing changes warrant stopping the drug and seeking urgent evaluation. People with significant cardiovascular disease should not assume a drug studied in relatively healthy populations is safe for them without a specific conversation.
On cost, generic tadalafil is inexpensive through ordinary pharmacies when prescribed for an approved indication, as covered in MedicalDaily's explainer on daily and as-needed dosing. A $70 monthly longevity subscription is not the cheapest route to the same molecule, and it is unlikely to be covered by insurance when the stated purpose is not an approved use.
The honest summary is that this sits in a genuine gray zone. The signal in the data has persuaded some serious cardiologists that the question deserves a trial. It has not persuaded them that the answer is known. Anyone weighing this should treat it as an open research question discussed with their own clinician, not as a settled preventive therapy sold by subscription.
Key Questions Answered
Is tadalafil approved for heart health or longevity? No. It is approved for erectile dysfunction, for pulmonary arterial hypertension, and for symptoms of an enlarged prostate. Preventing heart attack, stroke, or dementia is not an approved use.
Does the research show it works? Large analyses of medical records show lower rates of cardiovascular death, overall death, and dementia among men taking it. Those studies show association, not cause, and no randomized trial has tested the question.
Why has nobody run the trial? Generic versions are already available, so manufacturers have little commercial incentive to fund large and expensive prospective studies.
Do doctors recommend it for this? Not routinely. A specialist panel reached consensus that low-dose tadalafil is appropriate for a specific subset of men at elevated cardiovascular risk, which is much narrower than how it is being marketed.
Is it safe for women? The drug is far less studied in women, and the observational findings come overwhelmingly from men. Some clinics offer it to women anyway.
What is the most serious interaction? It must not be taken with nitrate medications for chest pain, a combination that can cause a dangerous drop in blood pressure. It also interacts with alpha blockers.
What should someone do if they are curious? Discuss it with a clinician who has their full medication list and cardiovascular history, rather than completing an online questionnaire.
